KRAS and non-small cell lung carcinoma: The study demonstrated that NSCLC models with KRAS mutations displayed a greater sensitivity to pemetrexed, and the expression of KRAS RNA changed after treatment with pemetrexed, leading to decreased angiogenesis, possibly because KRAS-mutant cells were more dependent on the folate metabolic pathway164.